The role of the community pharmacy in the fight against antimicrobial resistance: A Survey in Italy
Main Article Content
Keywords
AntiMicrobial Resistance, AMR, questionnaire, information campaign, Community pharmacy
Abstract
Background: In the last decades, the inappropriate use of anti-microbials has accelerated the spread of AntiMicrobial Resistances (AMR). Italy has been among the countries in Europe with the highest percentages of resistance to the principal classes of antibiotics. Objective. in 2024 we developed a nationwide project in Italy titled “Antimicrobial resistance: it’s time to act”. The main objectives were: to increase the knowledge among community pharmacists of the phenomenon of AMR and Group A Streptococcus (GAS) infections; to investigate, among the population attending community pharmacies, the knowledge of the risks associated with the incorrect use of antibiotics (Phase 1), and the prevalence of GAS infections (Phase 2). Methods. The study was conducted in Italian in community pharmacies. Phase 1 was subdivided into two phases: in Phase 1A, the investigation was carried out by using a self- administered questionnaire, whereas in Phase1B, the same questionnaire was administered to users by the community pharmacist. In Phase 2, data were gathered recording the results of rapid tests to detect GAS infections. Results. During Phase 1, data was collected in 778 pharmacies. 14.507 subjects were interviewed. During phase 2, 218 pharmacies participated and 1.914 subjects were enrolled. The Phase 1 investigation showed that there was a significant lack of awareness of AMR among the study population. The data collected enable us to highlight the need for health care professionals to provide the education of the Italian population on the issue of AMR. Regarding Phase 2, it is possible to affirm that the presence of general symptoms consistent with a GAS infection was not at all predictive of a positive result to the rapid test with the exception of the 0-10-year-old age group. Considering, however, more specifically those who declared a set of symptoms affecting the throat, the likelihood that a subject has a positive test rises significantly with age. Conclusions. In light of these results, and the fact that community pharmacies are among the health services most easily accessible to the general public, their active involvement in any campaign to raise awareness and educate the population on the topic of AMR should be considered.
References
2. World Health Organization. Antimicrobial resistance. 2023 Nov 21. Available from: https://www.who.int/health-topics/antimicrobial-resistance
3. Italian Higher Institute of Health. National plan of contrast to antibiotic resistance 2022–2025. 2022 Nov 30. Available from: https://www.epicentro.iss.it/antibiotico-resistenza/pncar-2022
4. Stapleton PD, Taylor PW. Methicillin resistance in Staphylococcus aureus: mechanisms and modulation. Sci Prog. 2002;85(Pt 1):57-72. doi:10.3184/003685002783238870.
5. McGuinness WA, Malachowa N, DeLeo FR. Vancomycin resistance in Staphylococcus aureus. Yale J Biol Med. 2017;90(2):269-281.
6. Aslam B, Wang W, Arshad MI, Khurshid M, Muzammil S, Rasool MH, Nisar MA, Alvi RF, Aslam MA, Qamar MU, Salamat MKF, Baloch Z. Antibiotic resistance: a rundown of a global crisis. Infect Drug Resist. 2018;11:1645-1658. doi:10.2147/IDR.S173867.
7. Manyi-Loh C, Mamphweli S, Meyer E, Okoh A. Antibiotic use in agriculture and its consequential resistance in environmental sources: potential public health implications. Molecules. 2018;23(4):795. doi:10.3390/molecules23040795.
8. Maron DF, Smith TJ, Nachman KE. Restrictions on antimicrobial use in food animal production: an international regulatory and economic survey. Global Health. 2013;9:48. doi:10.1186/1744-8603-9-48.
9. Mancuso G, Midiri A, Gerace E, Biondo C. Bacterial antibiotic resistance: the most critical pathogens. Pathogens. 2021;10(10):1310. doi:10.3390/pathogens10101310.
10. Prigitano A, Romanò L, Auxilia F, Castaldi S, Tortorano AM. Antibiotic resistance: Italian awareness survey 2016. J Infect Public Health. 2018;11(1):30-34. doi:10.1016/j.jiph.2017.02.010.
11. World Health Organization. Antimicrobial resistance: accelerating national and global responses. 2024 Apr 11. Available from: https://apps.who.int/gb/ebwha/pdf_files/WHA77/A77_5-en.pdf
12. Presidency of the Council of Ministers - Polygraphic Institute and State Mint. Legge 20 novembre 2017, n. 167 “Disposizioni per l’adempimento degli obblighi derivanti dall’appartenenza dell’Italia all’Unione europea - Legge europea 2017”. 2017 Nov 27. Available from: https://www.normattiva.it/uri-res/N2Ls?urn:nir:stato:legge:2017-11-20;167!vig=
13. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2023–2021 data. 2023 Apr 14. Available from: https://www.ecdc.europa.eu/en/publications-data/antimicrobial-resistance-surveillance-europe-2023-2021-data
14. Italian Higher Institute of Health. Group A Streptococcal infections. 2024 Apr 23. Available from: https://www.issalute.it/index.php/la-salute-dalla-a-alla-z-menu/i/infezioni-da-streptococco-di-gruppo-a
15. Mustafa Z, Ghaffari M. Diagnostic methods, clinical guidelines, and antibiotic treatment for group A streptococcal pharyngitis: a narrative review. Front Cell Infect Microbiol. 2020;10:563627. doi:10.3389/fcimb.2020.563627.
16. Bessen DE, McShan WM, Nguyen SV, Shetty A, Agrawal S, Tettelin H. Molecular epidemiology and genomics of group A Streptococcus. Infect Genet Evol. 2015;33:393-418. doi:10.1016/j.meegid.2014.10.011.
17. Ministry of Health. Circular 12/15/22 “Increased incidence of scarlet fever and invasive group A streptococcal infection – more countries”. 2022 Dec 15. Available from: https://www.pnrr.salute.gov.it
18. National Federation of Pharmacy Owners. Medicines and pharmacies: the presence of pharmacies on the territory. 2024 Mar 31. Available from: https://www.federfarma.it
19. Alshehri AA, Jalal Z, Cheema E, Haque MS, Jenkins D, Yahyouche A. Impact of the pharmacist-led intervention on the control of medical cardiovascular risk factors for the primary prevention of cardiovascular disease in general practice: a systematic review and meta-analysis of randomised controlled trials. Br J Clin Pharmacol. 2020;86(1):29-38. doi:10.1111/bcp.14164.
20. Solidoro P, Braido F, Baratta F, Bagnasco D, Esposito R, Aggeri M, Brusa P. FEV6 assessment in spirometric abnormalities screening: the first population-based study in Italian pharmacies. Panminerva Med. 2013;55(1):87-92.
21. Giaccone M, Baratta F, Allais G, Brusa P. Prevention, education and information: the role of the community pharmacist in the management of headaches. Neurol Sci. 2014;35(Suppl 1):1-4. doi:10.1007/s10072-014-1732-6.
22. Brusa P, Allais G, Rolando S, Baratta F, Giaccone M, Bussone G, Allais R, Benedetto C. Migraine attacks in the pharmacy: a gender subanalysis on treatment preferences. Neurol Sci. 2015;36(Suppl 1):93-95. doi:10.1007/s10072-015-2156-7.
23. Brusa P, Parente M, Allais G, Rolando S, Costa G, Gnavi R, Spadea T, Giaccone M, Mandelli A, Mana M, Baratta F, Benedetto C, Bussone G. Community pharmacies as epidemiological sentinels of headache: first experience in Italy. Neurol Sci. 2017;38(Suppl 1):15-20. doi:10.1007/s10072-017-2908-7.
24. Baratta F, Allais G, Rolando S, Manzoni GC, Bussone G, Benedetto C, Scarinzi C, Gnavi R, Spadea T, Costa G, Parente M, Mana M, Giaccone M, Mandelli A, Brusa P. Prevention, education and counselling: the worldwide role of the community pharmacist as an epidemiological sentinel of headaches. Neurol Sci. 2019;40(Suppl 1):15-21. doi:10.1007/s10072-019-03794-7.
25. Brusa P, Allais G, Scarinzi C, Baratta F, Parente M, Rolando S, Gnavi R, Spadea T, Costa G, Benedetto C, Mana M, Giaccone M, Mandelli A, Manzoni GC, Bussone G. Self-medication for migraine: a nationwide cross-sectional study in Italy. PLoS One. 2019;14(1):e0211191. doi:10.1371/journal.pone.0211191.
26. Brusa P, Allais G, Rolando S, Baratta F, Giaccone M, Bussone G, Allais R, Benedetto C. Migraine attacks in the pharmacy: a gender subanalysis on treatment preferences. Neurol Sci. 2015;36(Suppl 1):93-95. doi:10.1007/s10072-015-2156-7.
27. Pappaccogli M, Ravetto Enri L, Perlo E, Di Monaco S, Pignata I, Baratta F, Rabbia F, Mana M, Veglio F, Brusa P. Assessment of a non-physician screening program for hypertension and cardiovascular risk in community pharmacies. Nutr Metab Cardiovasc Dis. 2019;29(12):1316-1322. doi:10.1016/j.numecd.2019.07.009.
28. Parente M, Pignata I, Gnavi R, Spadea T, Di Martino M, Baratta F, Brusa P. Assessment of non-adherence to oral metformin and atorvastatin therapies: a cross-sectional survey in Piedmont (Italy). Patient Prefer Adherence. 2020;14:261-266. doi:10.2147/PPA.S226206.
29. Gnavi R, Sciannameo V, Baratta F, Scarinzi C, Parente M, Mana M, Giaccone M, Cavallo Perin P, Costa G, Spadea T, Brusa P. Opportunistic screening for type 2 diabetes in community pharmacies. Results from a region-wide experience in Italy. PLoS One. 2020;15(3):e0229842. doi:10.1371/journal.pone.0229842.
30. Spadea T, Onorati R, Baratta F, Pignata I, Parente M, Pannacci L, Ancona D, Ribecco P, Costa G, Gnavi R, Brusa P. Monitoring adherence to pharmacological therapy and follow-up examinations among patients with type 2 diabetes in community pharmacies. Results from an experience in Italy. PLoS One. 2021;16(9):e0256478. doi:10.1371/journal.pone.0256478.
31. Fanelli E, Ravetto Enri L, Pappaccogli M, Fasano C, Di Monaco S, Pignata I, Baratta F, Eula E, Masera G, Mana M, Rabbia F, Brusa P, Veglio F. Knowledge on arterial hypertension in general population: results from a community pharmacy screening program. Nutr Metab Cardiovasc Dis. 2021;31(4):1081-1086. doi:10.1016/j.numecd.2021.01.004.
32. Baratta F, Pignata I, Vicenzi G, Enri LR, Quaglino P, Comandone A, Ala A, Icardi M, Spadi R, Brusa P. Oncological patient management on the territory: the results of a survey in the north-west of Italy. Pharm Pract (Granada). 2022;20(4):2716. doi:10.18549/PharmPract.2022.4.2716.
33. Baratta F, Pignata I, Onorati R, Gnavi R, Costa G, Brusa P, Spadea T. Monitoring and screening COPD in community pharmacies: experimentation in Italy. Pharm Pract (Granada). 2023;21(3):2854. doi:10.18549/PharmPract.2023.3.2854.
34. Italian Higher Institute of Health. Pharmacists for health. 2020. Available from: https://www.epicentro.iss.it/guadagnare-salute/comunicazione/farmacisti
35. Baratta F, Stura I, Ravetto Enri L, Parente M, Migliaretti G, Brusa P. The knowledge of antimicrobial resistance: a survey in the community pharmacies of north-west Italy. Pharmacy Practice. 2025;23(4):3347.
36. Presidency of the Council of Ministers - Polygraphic Institute and State Mint. Decreto Legislativo 3 Ottobre 2009, n. 153 “Individuazione di nuovi servizi erogati dalle farmacie nell’ambito del Servizio sanitario nazionale…”. 2009 Nov 4. Available from: https://www.normattiva.it
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.